A 28-year-old woman with PCOS and BMI 34 kg/m² has oligo-ovulation and a partner with normal semen analysis. She has failed 3 cycles of letrozole (5 mg days 3–7). Which second-line intervention is supported by the largest RCT evidence and demonstrated non-inferior live birth rates compared to laparoscopic ovarian drilling in PCOS?
- A Clomiphene citrate 100 mg days 3–7
- B Laparoscopic ovarian drilling with electrocautery
- C Metformin combined with letrozole at higher dose
- D Low-dose FSH gonadotropin ovulation induction with monitoring ✓
Explanation
After failure of first-line oral ovulation induction (letrozole is now preferred over clomiphene per ESHRE/ASRM 2023 PCOS guidelines), second-line options are gonadotropin ovulation induction or laparoscopic ovarian drilling (LOD). Multiple RCTs and meta-analyses (including Cochrane reviews) show comparable cumulative pregnancy and live birth rates between low-dose FSH gonadotropin protocols and LOD. However, gonadotropins avoid surgical risks and are reversible; LOD has the risk of ovarian adhesions and diminished ovarian reserve. In a woman with BMI 34 and three failed letrozole cycles, FSH-stimulated cycles with ultrasound monitoring represent the evidence-supported medical second-line approach.
Reference: Shaw's Textbook of Gynaecology, 17th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.